Key facts
- Centerline Biomedical’s last known valuation is $67.2M (Jun 2022).
- It has raised $79.4M across 4 recorded rounds; the latest was Early Stage VC ($10.8M) in Apr 2025.
- Notable investors include MedTech Innovator, Jumpstart Ventures, JobsOhio Ventures, Gana Yantrika Enterprises, Cleveland Clinic — 15 tracked in total.
- Centerline Biomedical has filed 4 Form Ds with the SEC since 2023, most recently Apr 2025 ($10.8M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Centerline Biomedical
Funding rounds
4 roundsAbout Centerline Biomedical
Developer of three-dimensional visualization and real-time navigation system designed to improve endovascular procedures and reduce radiation exposure. The company's navigation system is a non-x-ray-based multi-dimensional global positioning system that provides greater surgical precision and control, enabling physicians to perform optimal, radiation-free image-guided endovascular surgery.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2014
- Employees
- 46
- Website
- centerlinebiomedical.com/
- Ownership
- Privately Held (backing)
Centerline Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Centerline Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Centerline Biomedical in its N-PORT filings yet. We sweep new filings monthly.